0GO Stock Chart & Stats
€0.03
€0.00(0.00%)
At close: 4:00 PM EDT
€0.03
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume21.77K
Average Volume (3M)N/A
Market Cap
€15.83M
Enterprise Value€3.06M
Total Cash (Recent Filing)€1.08M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-33.75
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,775,721,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)3.55
Price to Sales (P/S)523.56
P/FCF Ratio-3.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no debt reduces interest and refinancing burdens, preserving financial flexibility while the company develops its platform. This gives N4 Pharma more room to direct available resources toward research, partnerships, and value-creating programs rather than servicing leveraged obligations.
Nuvec Platform BreadthA proprietary delivery platform with applications across vaccines, oncology, immuno-oncology, and nucleic-acid or protein therapeutics offers several potential development pathways. Broader applicability can support partnering opportunities and reduce reliance on a single therapeutic program over time.
Multiple Partnering Revenue ChannelsThe partnering model can create several economic entry points as programs advance, including upfront funding, research payments, milestones, and eventual royalties. This structure could allow platform progress to generate value before commercial products are independently marketed by the company.
Bears Say
Persistent UnprofitabilityDeep and persistent losses show that the current revenue base does not cover operating costs, leaving profitability dependent on successful development and partnering outcomes. Continued negative margins can erode capital and make durable earnings generation difficult until programs mature.
Ongoing Cash BurnNegative operating and free cash flow means the business is not self-funding and must continue managing its cash resources while advancing Nuvec. Even though outflows narrowed versus 2023, recurring cash usage can constrain research investment and increase reliance on future financing or partner funding.
Small, Volatile Revenue BaseA small and volatile revenue base provides limited visibility into the company’s underlying commercial traction. The sharp 2025 increase from a low starting point may not yet demonstrate a repeatable growth engine, making future performance highly dependent on securing and progressing collaborations.
N4 Pharma News
0GO FAQ
What was N4 Pharma PLC’s price range in the past 12 months?
N4 Pharma PLC lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is N4 Pharma PLC’s market cap?
N4 Pharma PLC’s market cap is €15.83M.
When is N4 Pharma PLC’s upcoming earnings report date?
N4 Pharma PLC’s upcoming earnings report date is Sep 24, 2026 which is in 10 days.
How were N4 Pharma PLC’s earnings last quarter?
N4 Pharma PLC released its earnings results on Jun 23, 2026. The company reported -€0.001 earnings per share for the quarter.
Is N4 Pharma PLC overvalued?
According to Wall Street analysts N4 Pharma PLC’s price is currently Overvalued.
Does N4 Pharma PLC pay dividends?
N4 Pharma PLC does not currently pay dividends.
What is N4 Pharma PLC’s EPS estimate?
N4 Pharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does N4 Pharma PLC have?
N4 Pharma PLC has 1,775,721,000 shares outstanding.
What happened to N4 Pharma PLC’s price movement after its last earnings report?
N4 Pharma PLC reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of N4 Pharma PLC?
Currently, no hedge funds are holding shares in DE:0GO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
N4 Pharma PLC
Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
Eco Animal Health
―
Chill Brands Group PLC
―
Mountfield
―
Provexis
―
Shield Therapeutics
―